Belite Bio (BLTE) Receivables - Accured (2025)
Belite Bio (BLTE) posted quarterly Receivables - Accured of $634000.0 for Q4 2025.
Belite Bio (BLTE) Receivables - Accured (2025) Analysis & Trends
Belite Bio's Receivables - Accured history runs 1 years deep, the most recent figure standing at $634000.0 for Q4 2025.
- In Q4 2025, Receivables - Accured changed N/A year-over-year to $634000.0; the TTM figure through Dec 2025 stood at $634000.0 (changed N/A YoY), while the FY2025 annual figure was $634000.0, changed N/A from the prior year.
- Receivables - Accured for Q4 2025 stood at $634000.0.
- The five-year high for Receivables - Accured was $634000.0 in Q4 2025, with the low at $634000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 634,000.00 |
| Dec 31, 2025 | 634,000.00 |